News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genaissance Pharmaceuticals, Inc. (GNSC) Invites You To Participate In Its Fourth Quarter 2004 Conference Call



10/19/2005 5:12:37 PM

NEW HAVEN, Conn., Feb. 3 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. today announced that the Company would conduct a conference call on Thursday, February 10, 2005, at 11:30 a.m. Eastern time (ET), in conjunction with the release of its financial results for the fourth quarter ended December 31, 2004.

"The past year's activities have put us in a strong position to achieve major objectives in our partnering and portfolio development programs," said Kevin Rakin, President and Chief Executive Officer of Genaissance. "The revenue growth we expect in 2005 should narrow our losses and potentially bring us to positive operating cash flow by the fourth quarter, based on current levels of program funding."

To participate in this conference call, dial 913-981-5510, confirmation code 2415972, shortly before 11:30 a.m. ET. A replay of the call will be available from 2:30 p.m. ET through midnight Wednesday, February 16, 2005. The replay number is 719-457-0820, confirmation code 2415972.

Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy enables Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit our website at: http://www.genaissance.com/.

Genaissance Pharmaceuticals, Inc.

CONTACT: Rhonda Chiger, of Rx Communications Group, +1-917-322-2569,rchiger@RxIR.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES